Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 4.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 822,582 shares of the company’s stock after buying an additional 34,453 shares during the period. JPMorgan Chase & Co. owned approximately 0.11% of Roivant Sciences worth $9,493,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gladius Capital Management LP bought a new stake in Roivant Sciences during the third quarter worth approximately $35,000. Point72 Hong Kong Ltd acquired a new position in shares of Roivant Sciences during the 2nd quarter valued at $36,000. US Bancorp DE increased its position in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares during the period. Quarry LP bought a new stake in shares of Roivant Sciences in the 2nd quarter worth $53,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of Roivant Sciences by 23.2% in the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after buying an additional 1,603 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $10.74 on Tuesday. The company’s 50 day simple moving average is $11.85 and its 200 day simple moving average is $11.59. Roivant Sciences Ltd. has a fifty-two week low of $9.69 and a fifty-two week high of $13.06. The firm has a market capitalization of $7.82 billion, a P/E ratio of 1.90 and a beta of 1.27.

Insider Activity

In other news, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00. Following the sale, the chief operating officer now directly owns 617,470 shares in the company, valued at $7,193,525.50. The trade was a 13.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CIO Mayukh Sukhatme sold 185,946 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total value of $2,231,352.00. Following the completion of the sale, the executive now directly owns 18,836,547 shares in the company, valued at approximately $226,038,564. This represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,942,629 shares of company stock valued at $23,071,486 in the last quarter. Company insiders own 7.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ROIV. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.